Panel Discussion: Future Directions & Strategic Investment to Fuel the Next Wave of Neuropsychiatric Therapeutics

• How emerging scientific modalities such as circuit level biomarkers, data integrated platforms, and next generation neuroplastogens are shaping the future landscape of neuropsychiatric innovation
• What investors and R&D leaders look for in early stage assets, including differentiated mechanisms, strong biomarker strategies, and clear pathways to clinical and commercial de risking
• How strategic capital allocation across discovery, translational technologies, and Phase 2/3 ready programs can build sustainable, multi mechanism therapeutic pipelines
• Where the field is heading next, and how cross disciplinary innovation and coordinated investment can accelerate the next transformative wave in neuropsychiatric therapeutics

Speakers:

Paul Matteis

Managing Director & Head of Therapeutics Research

Stifel

Natalie Sacks

Partner

Novo Holdings US

Chris Weyrer

Principal

Vida Ventures

Jason Pitts

Principal

General Atlantic

Ritu Baral

Managing Director, Health Care – Biotechnology Research Analyst

Cowen

Aaron Koenig

Chief Medical Officer

Syremis Therapeutics